Literature DB >> 28417532

Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes.

Kenneth Cusi1, Arun J Sanyal2, Shuyu Zhang3, Mark L Hartman3, Juliana M Bue-Valleskey3, Byron J Hoogwerf3, Axel Haupt3.   

Abstract

We investigated non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes (T1D), and in insulin-naïve and insulin-treated patients with type 2 diabetes (T2D). Baseline data from patients who had liver fat content (LFC) evaluated by magnetic resonance imaging in four phase 3 studies of basal insulin peglispro (BIL) were analysed. Associations of NAFLD with clinical characteristics, glycaemic control and diabetes therapy were evaluated. The prevalence of NAFLD (defined as LFC ≥ 6%) was low in T1D (8.8%) but high in T2D, with greater prevalence in insulin-naïve (75.6%) vs insulin-treated (61.7%) T2D patients. LFC (mean ± SD) was higher in T2D patients (insulin-naïve, 13.0% ± 8.4%; insulin-treated, 10.2% ± 7.8%) than in T1D patients (3.2% ± 3.2%). In T2D, NAFLD was associated with several markers of insulin resistance. In all three populations, there was an absence of association of HbA1c with LFC, but insulin doses were higher in patients with NAFLD.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  insulin therapy; non-alcoholic fatty liver disease

Mesh:

Substances:

Year:  2017        PMID: 28417532     DOI: 10.1111/dom.12973

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  48 in total

1.  Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes.

Authors:  E Cipponeri; N Vitturi; V Mariano; F Boscari; S Galasso; C Crepaldi; G P Fadini; S Vigili de Kreutzenberg; M C Marescotti; E Iori; F Cavallin; L Sartori; A Baritussio; A Avogaro; D Bruttomesso
Journal:  J Endocrinol Invest       Date:  2019-03-07       Impact factor: 4.256

Review 2.  Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus.

Authors:  Giovanni Targher; Amedeo Lonardo; Christopher D Byrne
Journal:  Nat Rev Endocrinol       Date:  2017-12-29       Impact factor: 43.330

3.  Repurposing matrine for the treatment of hepatosteatosis and associated disorders in glucose homeostasis in mice.

Authors:  Ali Mahzari; Xiao-Yi Zeng; Xiu Zhou; Songpei Li; Jun Xu; Wen Tan; Ross Vlahos; Stephen Robinson; Ji-Ming Ye
Journal:  Acta Pharmacol Sin       Date:  2018-07-06       Impact factor: 6.150

4.  Diabetes symptoms predictors of health-related quality of life in adolescents and young adults with type 1 or type 2 diabetes.

Authors:  James W Varni; Alan M Delamater; Korey K Hood; Jennifer K Raymond; Kimberly A Driscoll; Jenise C Wong; Saleh Adi; Joyce P Yi-Frazier; Ellen K Grishman; Melissa A Faith; Sarah D Corathers; Jessica C Kichler; Jennifer L Miller; Elena M Doskey; Vincent P Aguirre; Robert W Heffer; Don P Wilson
Journal:  Qual Life Res       Date:  2018-05-21       Impact factor: 4.147

5.  A carbohydrate-reduced high-protein diet improves HbA1c and liver fat content in weight stable participants with type 2 diabetes: a randomised controlled trial.

Authors:  Mads J Skytte; Amirsalar Samkani; Amy D Petersen; Mads N Thomsen; Arne Astrup; Elizaveta Chabanova; Jan Frystyk; Jens J Holst; Henrik S Thomsen; Sten Madsbad; Thomas M Larsen; Steen B Haugaard; Thure Krarup
Journal:  Diabetologia       Date:  2019-07-23       Impact factor: 10.122

6.  Mauriac Syndrome: A Rare Hepatic Glycogenosis in Poorly Controlled Type 1 Diabetes.

Authors:  Marta Patita; Gonçalo Nunes; António Alves de Matos; Hélder Coelho; Cristina Fonseca; Jorge Fonseca
Journal:  GE Port J Gastroenterol       Date:  2019-01-29

Review 7.  Liver-targeting drugs and their effect on blood glucose and hepatic lipids.

Authors:  Amalia Gastaldelli; Norbert Stefan; Hans-Ulrich Häring
Journal:  Diabetologia       Date:  2021-04-20       Impact factor: 10.122

Review 8.  Non-alcoholic fatty liver diseases: current challenges and future directions.

Authors:  Elke Roeb
Journal:  Ann Transl Med       Date:  2021-04

Review 9.  Cellular protein markers, therapeutics, and drug delivery strategies in the treatment of diabetes-associated liver fibrosis.

Authors:  Chien-Yu Lin; Pratik Adhikary; Kun Cheng
Journal:  Adv Drug Deliv Rev       Date:  2021-04-20       Impact factor: 17.873

10.  Mean and visit-to-visit variability of glycated hemoglobin, and the risk of non-alcoholic fatty liver disease.

Authors:  Jee Hee Yoo; Mira Kang; Gyuri Kim; Kyu Yeon Hur; Jae Hyeon Kim; Dong Hyun Sinn; Sang-Man Jin
Journal:  J Diabetes Investig       Date:  2020-12-05       Impact factor: 4.232

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.